Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transection: short-term study.

Francis-Turner L, Valousková V

Neuroscience letters1 Jan 1996Cited by 42 (Europe PMC)

PMID8848264DOI10.1016/0304-3940(95)12240-0PepBankPUB-08848264

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats with fimbria-fornix lesions, Cerebrolysin retention test performance was comparable to non-lesioned controls.
In plain wordsIn rats with brain lesions, Cerebrolysin retention test performance was comparable to rats without lesions.
Peptide
Cerebrolysin
Outcome
No significant changeRetention test performance
Study
ratn: not reported in source
Unilateral fimbria-fornix lesion
Comparator
Non-lesioned controls
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
2.5 ml/kg/day · intraperitoneal injection · 14 daysAs given in this study (rat).
Source sentences
Summary
Groups CER and NGFCER were comparable to group INT in the retention or transfer test.
3 context sentences(design, population, supporting numbers)
Summary · context
Nootropic drug Cerebrolysin (EBEWE Arzneitmittel; 2.5 ml/kg/day, group CER) was applied via intraperitoneal injection (14 days).
Summary · context
Non-lesioned and lesioned only rats served as controls (groups INT and LES).
Summary · context
After a 14-day treatment, rats were tested using the retention test (1 day, four trials).
Report a problemFND-0884826401
02AnimalAnimal study (in vivo)Efficacy outcome
In rats with fimbria-fornix lesions, Cerebrolysin transfer test performance was comparable to non-lesioned controls.
In plain wordsIn rats with brain lesions, Cerebrolysin transfer test performance was comparable to rats without lesions.
Peptide
Cerebrolysin
Outcome
No significant changeTransfer test performance
Study
ratn: not reported in source
Unilateral fimbria-fornix lesion
Comparator
Non-lesioned controls
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
2.5 ml/kg/day · intraperitoneal injection · 14 daysAs given in this study (rat).
Source sentences
Summary
Groups CER and NGFCER were comparable to group INT in the retention or transfer test.
3 context sentences(design, population, supporting numbers)
Summary · context
Nootropic drug Cerebrolysin (EBEWE Arzneitmittel; 2.5 ml/kg/day, group CER) was applied via intraperitoneal injection (14 days).
Summary · context
Non-lesioned and lesioned only rats served as controls (groups INT and LES).
Summary · context
After a 14-day treatment, rats were tested using the retention test (1 day, four trials).
Report a problemFND-0884826402

Studies that did not test the peptide alone2

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

03AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Efficacy outcome
In rats with fimbria-fornix lesions, NGF plus Cerebrolysin retention test performance was comparable to non-lesioned controls.
In plain wordsIn rats with brain lesions, NGF plus Cerebrolysin retention test performance was comparable to rats without lesions.
Peptide
Cerebrolysin
Outcome
No significant changeCombination retention test performance
Study
ratn: not reported in source
Unilateral fimbria-fornix lesion
Comparator
Non-lesioned controls
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
Groups CER and NGFCER were comparable to group INT in the retention or transfer test.
4 context sentences(design, population, supporting numbers)
Summary · context
One group was formed by the rats treated with NGF (11 micrograms/ml) and Cerebrolysin (group NGFCER).
Summary · context
Nootropic drug Cerebrolysin (EBEWE Arzneitmittel; 2.5 ml/kg/day, group CER) was applied via intraperitoneal injection (14 days).
Summary · context
Non-lesioned and lesioned only rats served as controls (groups INT and LES).
Summary · context
After a 14-day treatment, rats were tested using the retention test (1 day, four trials).
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-0884826403
04AnimalNot a test of Cerebrolysin aloneAnimal study (in vivo)Efficacy outcome
In rats with fimbria-fornix lesions, NGF plus Cerebrolysin transfer test performance was comparable to non-lesioned controls.
In plain wordsIn rats with brain lesions, NGF plus Cerebrolysin transfer test performance was comparable to rats without lesions.
Peptide
Cerebrolysin
Outcome
No significant changeCombination transfer test performance
Study
ratn: not reported in source
Unilateral fimbria-fornix lesion
Comparator
Non-lesioned controls
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
Groups CER and NGFCER were comparable to group INT in the retention or transfer test.
4 context sentences(design, population, supporting numbers)
Summary · context
One group was formed by the rats treated with NGF (11 micrograms/ml) and Cerebrolysin (group NGFCER).
Summary · context
Nootropic drug Cerebrolysin (EBEWE Arzneitmittel; 2.5 ml/kg/day, group CER) was applied via intraperitoneal injection (14 days).
Summary · context
Non-lesioned and lesioned only rats served as controls (groups INT and LES).
Summary · context
After a 14-day treatment, rats were tested using the retention test (1 day, four trials).
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-0884826404

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.